Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Research & Development (2016 - 2025)

ProQR Therapeutics' Research & Development history spans 5 years, with the latest figure at $92.6 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 39.53% to $92.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.8 million, a 40.2% increase, with the full-year FY2025 number at $52.1 million, up 34.03% from a year prior.
  • Research & Development hit $92.6 million in Q4 2025 for ProQR Therapeutics, up from -$13.0 million in the prior quarter.
  • Over the last five years, Research & Development for PRQR hit a ceiling of $92.9 million in Q4 2022 and a floor of -$15.5 million in Q3 2022.
  • Historically, Research & Development has averaged $6.0 million across 5 years, with a median of -$10.5 million in 2021.
  • Biggest five-year swings in Research & Development: skyrocketed 751.81% in 2022 and later plummeted 74.39% in 2024.
  • Tracing PRQR's Research & Development over 5 years: stood at -$14.2 million in 2021, then skyrocketed by 751.81% to $92.9 million in 2022, then plummeted by 50.69% to $45.8 million in 2023, then skyrocketed by 44.91% to $66.4 million in 2024, then soared by 39.53% to $92.6 million in 2025.
  • Business Quant data shows Research & Development for PRQR at $92.6 million in Q4 2025, -$13.0 million in Q3 2025, and -$12.9 million in Q2 2025.